Objec ves
To determine the prevalence of thrombocytopenia in the cri cally ill children and its rela onship with mortality in Pediatric intensive care unit (PICU) admi ed children.
Methodology
A prospec ve observa onal study was performed over a period of 12 months on 102 cri cally ill children admi ed in PICU who fulfilled the criteria. Two pa ents le the study due to financial problems and as outcome could not be assessed on them, they were excluded from the study. Platelet count was noted at the me of admission and co n s e c u ve l y fo r t h e i n i a l fo u r d ays at P I C U. Thrombocytopenia was defined as platelet count less than 150/nL. Mortality in PICU was recorded as primary outcome.
Results
The prevalence of thrombocytopenia during consecu ve 4 days was 34% (n=34) and at the me of admission in PICU was 16% (n=16) among 100 children analysed in the study. The mortality in the PICU was 27% (n=27). Mortality among thrombocytopenic children was 61.7% (n=21) as compared to 7.6% (n=5) in non-thrombocytopenic children (p=<0.001). Mortality was 18 mes more for those who were thrombocytopenic at the me of admission as compared to those who subsequently developed thrombocytopenia during course of stay in PICU.
Conclusion
Thrombocytopenia has significant associa on with increased mortality. Thrombocytopenic children at the me of admission have more likelihood of mortality than nonthrombocytopenic children in intensive care units.
INTRODUCTION
Platelets are non-nucleated cellular fragments produced by megakaryocytes within the bone marrow and other ssues. They circulate with a life span of 10-14 days. The normal 9 1 platelet count is 150-450×10 /L. They play a pivotal role in normal hemostasis and thrombus forma on, which can be beneficial as well as poten ally harmful. In sepsis, they aggregate at sites of inflamma on leading to impaired microcircula on and organ dysfunc on .Beneficial effects include reducing vascular permeability, media ng inflammatory processes, promo ng wound healing and host defense mechanisms. This is a ributed to bioac ve molecules they release on ac va on such as ADP (adenosinediphosphate), ATP (adenosine triphosphate),
2+
Ca , coagula on factors, prostaglandins, thromboxane A2, [1] [2] [3] histamine and serotonin.
Thrombocytopenia refers to a reduc on in platelet count to 1 <150/nL. Various causes have been iden fied for the occurrence of thrombocytopenia like presence of disseminated intravascular coagula on, increased destruc on by immune/non-immune mechanisms, reduced produc on due to congenital/acquired causes, increased consump on or abnormal sequestra on of platelets within an enlarged 1, 4 spleen or other organ or a combina on of these. Certain drugs also cause thrombocytopenia for example heparin, a n bio cs (Linezolid, Vancomycin, betalactams, Trimethoprim/ sulphamethoxazole, Fluroquinolone, Rifampin) and an convulsants (Phenytoin, Diazepam, Valporic acid ) which are commonly used in intensive care 4 units. Thrombocy-topenia is associated with worse outcomes in pa ents with acute respiratory distress syndrome, which is most commonly caused by infec on and marked by alveolar-capillary barrier disrup on. However, the mechanisms by which platelets protect the lung alveolar-capillary barrier during infec ous injury remain unclear.
Thrombocytopenia is common among pa ents admi ed to the intensive care unit (ICU). Mul ple pathophysiological mechanisms may contribute, including thrombin-mediated platelet ac va on, dilu on, hemophagocytosis, extracellular histones, ADAMTS13 gene muta on and complement ac va on. From the clinical perspec ve, the development of thrombocytopenia in the ICU usually indicates serious organ system derangement and physiologic decompensa on rather than a primary hematologic disorder. Thrombocytopenia is associated with bleeding, transfusion, and adverse clinical outcomes including death, though few deaths are directly a ributable to bleeding. The assessment of thrombocytopenia begins by looking back to the pa ent's medical history and presen ng illness. This past informa on, combined with careful observa on of the platelet trajectory in the context of the pa ent's clinical course, offers clues to the diagnosis 5 and prognosis.
Thrombocytopenia reflects the severity of dysfunc on in blood-clo ng systems. A low platelet count is one indicator of organ dysfunc on in intensive care unit (ICU) scoring systems, such as the Sequen al Organ Failure Assessment (SOFA) score. Platelet count is also used in the diagnosis of sepsis-induced coagulopathy and disseminated intravascular 6 coagula on. Furthermore, the clinical significance of platelet count had increased because of recent changes in the defini on of sepsis, with organ dysfunc on now required for diagnosis. However, the precise mechanism of thrombocytopenia and its associa on with disease severity 7 and outcome in sepsis remains unclear.
Thrombocytopenia is commonly seen in cri cally ill pa ents. In addi on, some pa ents, such as those with uremia or vWD, may have dysfunc onal platelets despite normal counts. When mild, thrombocytopenia may not increase the bleeding risk substan ally, but severe thrombocytopenia is associated with both increased bleeding risk and higher mortality. As the most common coagulopathy in the ICU, the e ology of low platelet counts is o en mul factorial resul ng from the underlying disease state, medica ons, or as a result of consump on of thrombi. Although thrombocytopenia o en improves with treatment of the underlying illness, an in-depth understanding of the causes of thrombocytopenia and subsequent ac on may raise platelet counts and prevent unnecessary deferment of invasive procedures or exposure to platelet transfusion risks 5, 8 in cri cally ill pa ents.
Thrombocytopenia is one of the most common laboratory abnormali es in intensive care unit pa ents with an 5, 6, [8] [9] [10] [11] [12] incidence range of 15% to 50%. Thrombocytopenia can be a life-threatening condi on encountered in the ICU as it has been associated with spontaneous bleeding requiring platelets and fresh frozen plasma which ul mately results in 7 significant morbidity and mortality. Platelet count been studied for being an independent prognos c risk factor in ICU pa ents and linked to increased mortality, morbidity, and length of stay, independent of severity of illness or the 6, 7 number of dysfunc onal organs at baseline. The advantage of using platelets as a predictor of ICU outcome, is the dynamic nature of daily platelet counts which takes the disease progression into account in contrast to various mortality scores which use only the worst parameters within first 24h a er admission or at admissionlike PRISM and PIM. Serial platelet counts can be used to complement scoring systems such as pediatric risk of mortality (PRISM) score and pediatric index of mortality (PIM) score, as the informa on is dynamic and reflec ve of the evolu on of the disease process. In addi on, it is universally available, simple inves ga on and, unlike scoring systems does not involve 7 calcula ons or algorithms.
Thrombocytopenia is consistently associated with increased risks of bleeding, transfusion, and death; however, the effec veness of platelet transfusion to stop bleeding, reduce transfusion of other blood components, or improve clinical outcomes is uncertain. The need for evidence addressing this uncertainty is especially relevant in the ICU. Past prac ces of liberally correc ng abnormal laboratory values (eg, hemoglobin, albumin) or aggressively suppor ng deranged physiologic parameters that are recognized to be popula on and especially in our part of world. Hence this study was conducted in our setup to establish a rela onship between the platelet counts and outcome in cri cally ill children admi ed in PICU as there is paucity of such studies in Nepal.
METHODOLOGY
This is a hospital based prospec ve observa onal study conducted in Nobel medical college and teaching hospital, Biratnagar, Nepal conducted over a period of one year from August 2017 to July 2018. A er ethical clearance from ins tu onal review commi ee, data was collected from 102 consecu vely admi ed cases in PICU during the study period except those mee ng the exclusion criteria. The sample size was calculated based on a similar 10 research conducted in India by Agrawal S et al. By mortality rate comparison, es mated sample size for two-sample comparison of propor ons sample size was determined to be 102. Two pa ents le the study due to financial problems and as outcome could not be assessed were excluded from the study.
A er the admission of the pa ent in PICU, informed consent was taken from the parents/caretakers a er explaining about the study. Pa ent par culars and demographic informa on were collected according to the prepared performa. The pa ents who failed to give consent, le PICU against medical advice or were diagnosed cases of hematological malignancy were excluded.
Laboratory inves ga ons were done at the me of admission including complete blood count, renal func on test, random blood sugar and other relevant inves ga ons. Platelet count at the me of PICU admission was recorded and similarly daily platelet counts for ini al 4 days were recorded. Platelet count was done by hematology automated analyzer Durui bcc-3000B Tokyo, Japan. Thrombocytopenia was defined as platelet count less than 150 n/L and graded as mild, moderate, severe and very severe if platelet count <150 11 n/L ,< 100 n/L , <50n/L and <20 n/L respec vely.
The collected data was coded and entered into Microso excel and transferred to sta s cal package for social sciences (SPSS) version 20 for analysis. Differences in propor on between the groups were analyzed with Chi -Square test. p value <0.05 was considered significant.
RESULTS
In the study a total 102 children admi ed in the pediatric intensive care unit were analyzed. Among these children 80 got admi ed from ER whereas 22 from pediatric ward. There was male preponderance in our study with 62%(n=62) males and 38% (n=38) females. Largest group of pa ents were between 1 to 5 years accoun ng 30% (n=30) and smallest group of age between 6 to 10 years being 21% (n=21),while less than 1 year age group consis ng of 23% (n=23) and more than 10 years of age group being 26% (n=26).
Figure 1:
Age and sex distribu on of pa ents admi ed in PICU.
Among 102 pa ents admi ed to our PICU, 16% of them had thrombocytopenia at the me of admission, and 34 % had t h r o m b o c y t o p e n i a i n c l u d i n g t h o s e w h o w e r e thrombocytopenic at admission and those who developed thrombocytopenia by fourth day of admission.
Among thrombocytopenic pa ents 41.17%(n=14) developed mild thrombocytopenia, 32.3%(n=11) moderate,26.4% (n=9)developed severe thrombocytopenia. The overall mortality in the PICU was found to be 27% (n=27). There was 18 mes more risk of mortality among thrombocytopenic pa ent compared to non thrombocytopenic as odd ra o was 18 at 95%CI. 
DISCUSSION
The present prospec ve observa onal study was conducted to determine a rela onship between platelet count and outcome in cri cally ill children admi ed in PICU Nobel Medical Teaching Hospital, Biratnagar, Nepal. In the present study 102 pa ents consecu vely admi ed to PICU were studied. Among them 62(62%) were male and 38(38%) were female(Male: Female ra o = 1.6:1). A similar study done by 10 Agrawal S et al revealed male: female ra o of 1.76:1.
In the present study,16% pa ents had thrombocytopenia at the me of admission which was similar to the study done by 10 by Agrawal S et al. In contrast, a similar study carried out by Olmez et al observed only 9.3% with thrombocytopenia at 11 the me of admission. The difference in the prevalence may be due to the exclusion of heparin and other medica ons related thrombocytopenia in that retrospec ve study.
Mortality rate of our PICU was 27% which was less than a 15 study done in PICU at Turkey (37.2%) by Yilmaz S et al . 
CONCLUSIONS
In this prospec ve observa onal study, platelet counts <150.0/nL was found to be common laboratory finding in PICU. Thrombocytopenic children had higher mortality than non-thrombocytopenic children admi ed in PICU. Thrombocytopenic children at the me of admission to PICU had 18 mes more likelihood of mortality in comparison to no-thrombocytopenic children.
LIMITATIONS OF THE STUDY
Limita ons of the present study are the confounding factors and treatment strategies not taken into considera on as scoring systems such as PRISM and PIM couldn't be applied due to lack of resources in our PICU which could iden fy the severity of illness. The present study has demonstrated an associa on between thrombocytopenia and worsened outcome;however, no assump on regarding causa on is implied.
